Skip to main content
SpringerLink
Log in

Drug-Eluting Coronary Stents

  • Chapter
Cardiovascular Medicine

  • 242 Accesses

Abstract

The history of the treatment of atherosclerotic coronary artery disease includes milestones such as coronary angiography,1 coronary revascularization,2 coronary artery bypass grafting,3,4 balloon angioplasty,5 coronary stents,6–9 the recognition that high pressure inflation and dual antiplatelet therapy improve the outcome after stent placement,10 and drug-eluting stents.11–14 It is difficult to argue which of these events was the most important, as none of them is a singular event but rather a culmination of many smaller pieces of a puzzle that are finally put together. It has been said that innovators stand on the shoulders of those who went before, and that is certainly true in the field of coronary revascularization.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Sones FM Jr, Shirey EK. Cine coronary arteriography. Mod Concepts Cardiovasc Dis 1962;31:735.

    PubMed  Google Scholar 

  2. Effler DB, Groves LK, Sones FM Jr, et al. Endarterectomy in the treatment of coronary artery disease. J Thorac Cardiovasc Surg 1964;47:98.

    PubMed  CAS  Google Scholar 

  3. Fergusson DJ, Shirey EK, Sheldon WC, et al. Left internal mammary artery implant—postoperative assessment. Circulation 1968;37:II24.

    PubMed  CAS  Google Scholar 

  4. Favaloro RG. Bilateral internal mammary artery implants. Operative technique—a preliminary report. Cleve Clin Q 1967;34:61.

    PubMed  CAS  Google Scholar 

  5. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978;1:263.

    Article  PubMed  CAS  Google Scholar 

  6. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701.

    Article  PubMed  CAS  Google Scholar 

  7. Roubin GS, King SB 3rd, Douglas JS Jr, et al. Intracoronary stenting during percutaneous transluminal coronary angioplasty. Circulation 1990;81:IV92.

    PubMed  CAS  Google Scholar 

  8. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation 1991;83:148.

    PubMed  CAS  Google Scholar 

  9. White CJ, Ramee SR, Collins TJ. Elective placement of the Wiktor stent after coronary angioplasty. Am J Cardiol 1994;74:274.

    Article  PubMed  CAS  Google Scholar 

  10. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676.

    PubMed  CAS  Google Scholar 

  11. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192.

    PubMed  CAS  Google Scholar 

  12. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315.

    Article  PubMed  CAS  Google Scholar 

  13. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773.

    Article  PubMed  CAS  Google Scholar 

  14. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221.

    Article  PubMed  CAS  Google Scholar 

  15. Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634.

    Article  PubMed  Google Scholar 

  16. Ahmed JM, Mintz GS, Weissman NJ, et al. Mechanism of lumen enlargement during intracoronary stent implantation: an intravascular ultrasound study. Circulation 2000;102:7.

    PubMed  CAS  Google Scholar 

  17. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44.

    PubMed  CAS  Google Scholar 

  18. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996;94:35.

    PubMed  CAS  Google Scholar 

  19. Kasaoka S, Tobis JM, Akiyama T, et al. Angiographic and intravascular ultrasound predictors of in-stent restenosis. J Am Coll Cardiol 1998;32:1630.

    Article  PubMed  CAS  Google Scholar 

  20. Kastrati A, Schomig A, Seyfarth M, et al. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999;99:1005.

    PubMed  CAS  Google Scholar 

  21. Chan AW, Moliterno DJ. Restenosis: the clinical issues. In: Topol EJ, ed. Textbook of Interventional Cardiology. Philadelphia: Saunders, 2003:415–454.

    Google Scholar 

  22. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327.

    PubMed  CAS  Google Scholar 

  23. Forrester JS, Fishbein M, Helfant R, et al. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991;17:758.

    PubMed  CAS  Google Scholar 

  24. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44.

    PubMed  CAS  Google Scholar 

  25. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 1999;10:499.

    Article  PubMed  CAS  Google Scholar 

  26. Nobuyoshi M, Kimura T, Nosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988;12:616.

    PubMed  CAS  Google Scholar 

  27. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis. Fact, fancy, and future. Circulation 1994;90:2070.

    PubMed  CAS  Google Scholar 

  28. Heublein B, Pethig K, Elsayed AM. Silicon Carbide Coating N A Semiconducting Hybrid Design of Coronary Stents N A Feasibility Study. J Invasive Cardiol 1998;10:255.

    PubMed  Google Scholar 

  29. Antoniucci D, Bartorelli A, Valenti R, et al. Clinical and angiographic outcome after coronary arterial stenting with the carbostent. Am J Cardiol 2000;85:821.

    Article  PubMed  CAS  Google Scholar 

  30. Kastrati A, Schomig A, Dirschinger J, et al. Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation 2000;101:2478.

    PubMed  CAS  Google Scholar 

  31. Edelman ER, Seifert P, Groothuis A, et al. Gold-coated NIR stents in porcine coronary arteries. Circulation 2001;103:429.

    PubMed  CAS  Google Scholar 

  32. Windecker S, Mayer I, De Pasquale G, et al. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation 2001;104:928.

    Article  PubMed  CAS  Google Scholar 

  33. Hamm C. A multicenter, randomized trial comparing silicon carbide coated stents with stainless steel stents in acute coronary syndrome (TRUST study). Circulation 2001;104(suppl):II.

    Google Scholar 

  34. Herrmann RA, Rybnikar A, Resch A, et al. Thrombogenicity of stainless steel coronary stents with a completely gold coated surface. J Am Coll Cardiol 1998;31:413A.

    Article  Google Scholar 

  35. Hoar PF, Wilson RM, Mangano DT, et al. Heparin bonding reduces thrombogenicity of pulmonary-artery catheters. N Engl J Med 1981;305:993.

    Article  PubMed  CAS  Google Scholar 

  36. Lindsay RM, Rourke J, Reid B, et al. Platelets, foreign surfaces, and heparin. Trans Am Soc Artif Intern Organs 1976;22:292.

    PubMed  CAS  Google Scholar 

  37. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998;352:673.

    Article  PubMed  CAS  Google Scholar 

  38. Vrolix MC, Legrand VM, Reiber JH, et al. Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). MENTOR Trial Investigators. Am J Cardiol 2000;86:385.

    Article  PubMed  CAS  Google Scholar 

  39. Wohrle J, Al-Khayer E, Grotzinger U, et al. Comparison of the heparin coated vs the uncoated Jostent—no influence on restenosis or clinical outcome. Eur Heart J 2001;22:1808.

    Article  PubMed  CAS  Google Scholar 

  40. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation 2003;107:2274.

    Article  PubMed  Google Scholar 

  41. Klugherz BD, Llanos G, Lieuallen W, et al. Twenty-eight-day efficacy and pharmacokinetics of the sirolimus-eluting stent. Coron Artery Dis 2002;13:183.

    Article  PubMed  Google Scholar 

  42. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188.

    Article  PubMed  CAS  Google Scholar 

  43. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res 2000;86:879.

    PubMed  CAS  Google Scholar 

  44. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimuseluting stent: should we be cautious? Circulation 2004;109:701.

    Article  PubMed  Google Scholar 

  45. Kristensen GB, Trope C. Epithelial ovarian carcinoma. Lancet 1997;349:113.

    Article  PubMed  CAS  Google Scholar 

  46. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;277:665.

    Article  PubMed  CAS  Google Scholar 

  47. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004.

    Article  PubMed  CAS  Google Scholar 

  48. Nishio K, Arioka H, Ishida T, et al. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Int J Cancer 1995;63:688.

    Article  PubMed  CAS  Google Scholar 

  49. Rosette C, Karin M. Cytoskeletal control of gene expression: depolymerization of microtubules activates NF-kappa B. J Cell Biol 1995;128:1111.

    Article  PubMed  CAS  Google Scholar 

  50. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995;95:1869.

    PubMed  CAS  Google Scholar 

  51. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000;36:2325.

    Article  PubMed  CAS  Google Scholar 

  52. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38.

    Article  PubMed  CAS  Google Scholar 

  53. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788.

    Article  PubMed  CAS  Google Scholar 

  54. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103:2289.

    PubMed  CAS  Google Scholar 

  55. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001;59:3.

    Article  PubMed  CAS  Google Scholar 

  56. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99:2164.

    PubMed  CAS  Google Scholar 

  57. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996;98:2277.

    Article  PubMed  CAS  Google Scholar 

  58. Marx SO, Jayaraman T, Go LO, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76:412.

    PubMed  CAS  Google Scholar 

  59. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998;98:82.

    PubMed  CAS  Google Scholar 

  60. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852.

    PubMed  CAS  Google Scholar 

  61. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999;10:1366.

    PubMed  CAS  Google Scholar 

  62. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991;251:283.

    Article  PubMed  CAS  Google Scholar 

  63. Carter AJ, Falotico R. The sirolimus-eluting Bx Velocity™ stent: preclinical data. In: Serruys PW, Rensing BJ, eds. Handbook of Coronary Stents. London: Martin Dunitz, 2002:349–358.

    Google Scholar 

  64. Farb A, John M, Acampado E, et al. Oral everolimus inhibits in-stent neointimal growth. Circulation 2002;106:2379.

    Article  PubMed  CAS  Google Scholar 

  65. Virmani R, Jones R, Kar S, et al. Everolimus and sirolimus drug-eluting stents are equally effective at reducing neointimal proliferation in a 28-day porcine coronary model, presented at the Transcatheter Cardiovascular Therapeutics, 2003, Washington, DC.

    Google Scholar 

  66. Grube E, Sonoda S, Ikeno F, et al. Six-and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004;109:2168.

    Article  PubMed  CAS  Google Scholar 

  67. Costa RA, Grube E, Negoita M, et al. Everolimus-eluting stents for the prevention of restenosis: results of the FUTURE II trial. J Am Coll Cardiol 2004;43:12A.

    Article  Google Scholar 

  68. Buellesfeld L, Grube E. ABT-578-eluting stents. The promising successor of sirolimus-and paclitaxel-eluting stent concepts? Herz 2004;29:167.

    Article  PubMed  Google Scholar 

  69. Grube E, Buellesfeld L. Rapamycin analogs for stent-based local drug delivery. Everolimus-and tacrolimus-eluting stents. Herz 2004;29:162.

    Article  PubMed  Google Scholar 

  70. Gerckens U, Silber S, Horstkotte D, et al. Evaluation of a tacrolimus-eluting coronary stent graft for treatment of saphenous vein graft lesions: procedural and 6-month follow-up results of the EVIDENT trial, presented at the Transcatheter Cardiovascular Therapeutics 2003, Washington, DC.

    Google Scholar 

  71. De Scheerder I, Wilczek K, Van Dorpe J, et al. Local angiopeptin delivery using coated stents reduces neointimal proliferation in overstretched porcine coronary arteries. J Invasive Cardiol 1996;8:215.

    PubMed  Google Scholar 

  72. Armstrong J, Gunn J, Arnold N, et al. Angiopeptin-eluting stents: observations in human vessels and pig coronary arteries. J Invasive Cardiol 2002;14:230.

    PubMed  Google Scholar 

  73. Kowk OH, Chow WH, Lee CH, et al. First human experience in angiopeptin-eluting stent: preliminary clinical outcome of the Stent With Angiopeptin (SWAN) trial. Am J Cardiol 2002;90(suppl 6A):72H.

    Google Scholar 

  74. Kutryk MJ, Foley DP, van den Brand M, et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 2002;39:281.

    Article  PubMed  CAS  Google Scholar 

  75. Kipshidze NN, Iversen P, Kim HS, et al. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter Cardiovasc Intervent 2004;61:518.

    Article  Google Scholar 

  76. Liu X, Huang Y, Hanet C, et al. Study of antirestenosis with the BioDivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Intervent 2003;60:172.

    Article  Google Scholar 

  77. Geraldes P, Sirois MG, Bernatchez PN, et al. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol 2002;22:1585.

    Article  PubMed  CAS  Google Scholar 

  78. New G, Moses JW, Roubin GS, et al. Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. Catheter Cardiovasc Intervent 2002;57:266.

    Article  Google Scholar 

  79. Abizaid A, Albertal M, Costa MA, et al. First human experience with the 17-beta-estradiol-eluting stent: the Estrogen and Stents to Eliminate Restenosis (EASTER) trial. J Am Coll Cardiol 2004;43:1118.

    Article  PubMed  CAS  Google Scholar 

  80. De Smet BJ, de Kleijn D, Hanemaaijer R, et al. Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig. Circulation 2000;101:2962.

    PubMed  Google Scholar 

  81. Gobeil F, Laflamme M, Bouchard M, et al. BioDivYsio stent coated with metalloproteinase inhibitor reduces neointimal hyperplasia in a porcine coronary artery restenosis model. Circulation 2001;104:II.

    Google Scholar 

  82. Aggarwal RK, Ireland DC, Azrin MA, et al. Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody. Circulation 1996;94:3311.

    PubMed  CAS  Google Scholar 

  83. Alt E, Haehnel I, Beilharz C, et al. Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. Circulation 2000;101:1453.

    PubMed  CAS  Google Scholar 

  84. Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107:381.

    Article  PubMed  Google Scholar 

  85. Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002;106:798.

    Article  PubMed  CAS  Google Scholar 

  86. Regar E, Serruys PW, Bode C, et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimuseluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002;106:1949.

    Article  PubMed  CAS  Google Scholar 

  87. Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559.

    Article  PubMed  Google Scholar 

  88. de la Fuente LM, Miano J, Mrad J, et al. Initial results of the Quanam drug eluting stent (QuaDS-QP-2) Registry (BARDDS) in human subjects. Catheter Cardiovasc Intervent 2001;53:480.

    Article  Google Scholar 

  89. Kataoka T, Grube E, Honda Y, et al. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 2002;106:1788.

    Article  PubMed  CAS  Google Scholar 

  90. Grube E, Lansky A, Hauptmann KE, et al. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Cardiol 2004;44:1368.

    PubMed  CAS  Google Scholar 

  91. Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004;109:1948.

    Article  PubMed  CAS  Google Scholar 

  92. Serruys PW, Ormiston JA, Sianos G, et al. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J Am Coll Cardiol 2004;44:1363.

    PubMed  CAS  Google Scholar 

  93. Lemos PA, Lee CH, Degertekin M, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003;41:2093.

    Article  PubMed  Google Scholar 

  94. Lemos PA, Saia F, Hofma SH, et al. Short-and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004;43:704.

    Article  PubMed  Google Scholar 

  95. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004;109:1930.

    Article  PubMed  Google Scholar 

  96. Colombo A, Stankovic G, Orlic D, et al. Modified T-stenting technique with crushing for bifurcation lesions: immediate results and 30-day outcome. Catheter Cardiovasc Intervent 2003;60:145.

    Article  CAS  Google Scholar 

  97. Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004;109:1366.

    Article  PubMed  Google Scholar 

  98. Pan M, Suarez de Lezo J, Pavlovic D, et al. Drug-eluting stents for bifurcating coronary lesions: a randomized comparison of simple versus complex-strategy approach (abst). J Am Coll Cardiol 2004;43:87A.

    Article  Google Scholar 

  99. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190.

    Article  PubMed  CAS  Google Scholar 

  100. Ellis SG, Tamai H, Nobuyoshi M, et al. Contemporary percutaneous treatment of unprotected left main coronary stenoses: initial results from a multicenter registry analysis 1994–1996. Circulation 1997;96:3867.

    PubMed  CAS  Google Scholar 

  101. Tan WA, Tamai H, Park SJ, et al. Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patients. Circulation 2001;104:1609.

    Article  PubMed  CAS  Google Scholar 

  102. Takagi T, Stankovic G, Finci L, et al. Results and long-term predictors of adverse clinical events after elective percutaneous interventions on unprotected left main coronary artery. Circulation 2002;106:698.

    Article  PubMed  Google Scholar 

  103. Park SJ, Hong MK, Lee CW, et al. Elective stenting of unprotected left main coronary artery stenosis: effect of debulking before stenting and intravascular ultrasound guidance. J Am Coll Cardiol 2001;38:1054.

    Article  PubMed  CAS  Google Scholar 

  104. Appelman YE, Piek JJ, Redekop WK, et al. Clinical events following excimer laser angioplasty or balloon angioplasty for complex coronary lesions: subanalysis of a randomised trial. Heart 1998;79:34.

    PubMed  CAS  Google Scholar 

  105. Chieffo A, Orlic D, Airoldi F, et al. Early and mid-term results of CYPHER stents in unprotected left main. J Am Coll Cardiol 2004;43:21A.

    Article  Google Scholar 

  106. Arampatzis CA, Lemos PA, Tanabe K, et al. Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. Am J Cardiol 2003;92:327.

    Article  PubMed  CAS  Google Scholar 

  107. Waksman R, Ajani AE, White RL, et al. Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. N Engl J Med 2002;346:1194.

    Article  PubMed  Google Scholar 

  108. Waksman R, Ajani AE, White RL, et al. Four-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis: results from a randomized clinical trial. J Am Coll Cardiol 2002;39:64A.

    Article  Google Scholar 

  109. Waksman R, Raizner AE, Yeung AC, et al. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet 2002;359:551.

    Article  PubMed  Google Scholar 

  110. Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000;101:2165.

    PubMed  CAS  Google Scholar 

  111. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336:1697.

    Article  PubMed  CAS  Google Scholar 

  112. Teirstein PS, Massullo V, Jani S, et al. Three-year clinical and angiographic follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 2000;101:360.

    PubMed  CAS  Google Scholar 

  113. Leon MB, Teirstein PS, Lansky AJ, et al. Intracoronary gamma radiation to reduce in-stent restenosis: The multicenter GAMMA 1 randomized clinical trial. J Am Coll Cardiol 1999;33:19A.

    Google Scholar 

  114. Leon MB, Teirstein PS, Moses J, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001;344:250.

    Article  PubMed  CAS  Google Scholar 

  115. Popma JJ, Suntharalingam M, Lansky AJ, et al. Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation 2002;106:1090.

    Article  PubMed  Google Scholar 

  116. Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003;107:24.

    Article  PubMed  CAS  Google Scholar 

  117. Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol 2003;41:184.

    Article  PubMed  CAS  Google Scholar 

  118. Saia F, Lemos PA, Sianos G, et al. Effectiveness of sirolimuseluting stent implantation for recurrent in-stent restenosis after brachytherapy. Am J Cardiol 2003;92:200.

    Article  PubMed  CAS  Google Scholar 

  119. Foley DP, Melkert R, Serruys PW. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty. Circulation 1994;90:1239.

    PubMed  CAS  Google Scholar 

  120. Hirshfeld JW Jr, Schwartz JS, Jugo R, et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART Investigators. J Am Coll Cardiol 1991;18:647.

    Article  PubMed  Google Scholar 

  121. Elezi S, Kastrati A, Neumann FJ, et al. Vessel size and longterm outcome after coronary stent placement. Circulation 1998;98:1875.

    PubMed  CAS  Google Scholar 

  122. Kastrati A, Schomig A, Dirschinger J, et al. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. Circulation 2000;102:2593.

    PubMed  CAS  Google Scholar 

  123. Azar AJ, Detre K, Goldberg S, et al. A meta-analysis on the clinical and angiographic outcomes of stents vs PTCA in the different coronary vessel sizes in the BENESTENT-1 and STRESS-1/2 trials. Circulation 1995;92:I.

    Google Scholar 

  124. Savage MP, Fischman DL, Rake R, et al. Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries. Stent Restenosis Study (STRESS) Investigators. J Am Coll Cardiol 1998;31:307.

    Article  PubMed  CAS  Google Scholar 

  125. Mehilli J, Kastrati A, Dirschinger J, et al. Comparison of stenting with balloon angioplasty for lesions of small coronary vessels in patients with diabetes mellitus. Am J Med 2002;112:13.

    Article  PubMed  Google Scholar 

  126. Doucet S, Schalij MJ, Vrolix MC, et al. Stent placement to prevent restenosis after angioplasty in small coronary arteries. Circulation 2001;104:2029.

    PubMed  CAS  Google Scholar 

  127. Hausleiter J, Kastrati A, Mehilli J, et al. Comparative analysis of stent placement versus balloon angioplasty in small coronary arteries with long narrowings (the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries [ISAR-SMART] Trial). Am J Cardiol 2002;89:58.

    Article  PubMed  Google Scholar 

  128. Schampaert E, Cohen EA, Schluter M, et al. for the C SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110–1115.

    Article  PubMed  CAS  Google Scholar 

  129. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942.

    Article  PubMed  CAS  Google Scholar 

  130. Stone GW, Ellis SG, Cannon L, et al. For the TAXUS V investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. A randomized controlled trial. JAMA 2005;294:1215–1223.

    Article  PubMed  CAS  Google Scholar 

  131. Lemos PA, Arampatzis CA, Saia F, et al. Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH registry). Am J Cardiol 2004;93:633.

    Article  PubMed  CAS  Google Scholar 

  132. Saia F, Lemos PA, Arampatzis CA, et al. Clinical and angiographic outcomes after overdilatation of undersized sirolimuseluting stents with largely oversized balloons: an observational study. Catheter Cardiovasc Intervent 2004;61:455.

    Article  Google Scholar 

  133. Wong SC, Baim DS, Schatz RA, et al. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. The Palmaz-Schatz Stent Study Group. J Am Coll Cardiol 1995;26:704.

    Article  PubMed  CAS  Google Scholar 

  134. Brener SJ, Ellis SG, Apperson-Hansen C, et al. Comparison of stenting and balloon angioplasty for narrowings in aortocoronary saphenous vein conduits in place for more than five years. Am J Cardiol 1997;79:13.

    Article  PubMed  CAS  Google Scholar 

  135. Savage MP, Douglas JS Jr, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997;337:740.

    Article  PubMed  CAS  Google Scholar 

  136. Ellis SG, Guetta V, Miller D, et al. Relation between lesion characteristics and risk with percutaneous intervention in the stent and glycoprotein IIb/IIIa era: an analysis of results from 10,907 lesions and proposal for new classification scheme. Circulation 1999;100:1971.

    PubMed  CAS  Google Scholar 

  137. Stone GW, Rogers C, Hermiller J, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003;108:548.

    Article  PubMed  Google Scholar 

  138. Stone GW, Cox DA, Babb J, et al. Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. J Am Coll Cardiol 2003;42:2007.

    Article  PubMed  Google Scholar 

  139. Schachinger V, Hamm CW, Munzel T, et al. A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol 2003;42:1360.

    Article  PubMed  CAS  Google Scholar 

  140. Ribeiro PA, Scavetta K, Oh C, et al. Long-term clinical results after stent implantation in old obstructed saphenous vein grafts. Chest 2000;118:750.

    Article  PubMed  CAS  Google Scholar 

  141. Kandzari DE, Goldberg S, Schwartz RS, et al. Clinical and angiographic efficacy of a self-expanding nitinol stent in saphenous vein graft atherosclerotic disease: the Stent Comparative Restenosis (SCORES) Saphenous Vein Graft Registry. Am Heart J 2003;145:868.

    Article  PubMed  Google Scholar 

  142. Reimers B, Columbo A, Tobis J. Bifurcation lesions. In: Colombo A, Tobis J, eds. Techniques in Coronary Artery Stenting. London: Martin Dunitz, 2000:171–204.

    Google Scholar 

  143. Lefevre T, Louvard Y, Morice MC, et al. Stenting of bifurcation lesions: classifications, treatments, and results. Catheter Cardiovasc Intervent 2000;49:274–283.

    Article  CAS  Google Scholar 

  144. Yamashita T, Nishida T, Adamian MG, et al. Bifurcation lesions: two stents versus one stent—immediate and follow up results. J Am Coll Cardiol 2000;35:1145–1151.

    Article  PubMed  CAS  Google Scholar 

  145. Gobeil F. Lefevre T, Guyon P, et al. Stenting of bifurcation lesions using the Bistent: a prospective dual-center study. Catheter Cardiovasc Intervent 2002;55:427–433.

    Article  Google Scholar 

  146. Garot P, Lefevre T, Savage M, et al. Nine-month outcome of patients treated by percutaneous coronary interventions for bifurcation lesions in the recent era. J Am Coll Cardiol 2005;46:606–612.

    Article  PubMed  Google Scholar 

  147. Colombo A, Stankovic G, Orlic D, et al. Modified t stenting technique with crushing for bifurcation lesions: immediate results and 30-day outcome. Catheter Cardiovasc Intervent 2003;60:145–151.

    Article  CAS  Google Scholar 

  148. Ge L, Airoldi F, Iakovou I, et al. Clinical and angiographic Outcome after Implantation of Drug Eluting Stents in Bifurcation Lesions with the Crush Stent Technique. J Am Coll Cardiol 2005;46:613–620.

    Article  PubMed  CAS  Google Scholar 

  149. Lei G, Airoldi F, Ioannis I, et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique. Importance of final kissing balloon post-dilation. J Am Coll Cardiol 2005;46:613–620.

    Article  CAS  Google Scholar 

  150. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004:109:1930–1932.

    Article  PubMed  Google Scholar 

  151. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drugeluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519–1521.

    Article  PubMed  CAS  Google Scholar 

  152. Schuhlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998;198:104–111.

    Google Scholar 

  153. Costa R, Mintz G, Carlier S, et al. Bifurcation coronary lesions treated with the “crush” technique. J Am Coll Cardiol 2005;46:599–605.

    Article  PubMed  Google Scholar 

  154. Lefevre T, Ormiston J, Guagliumi G, et al. The Frontier Stent Registry. J am Coll Cardiol 2005;46:592–598.

    Article  PubMed  Google Scholar 

  155. Iakovou I, Ge L, Columbo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol 2005;46:1446–1455.

    Article  PubMed  Google Scholar 

  156. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537.

    Article  PubMed  CAS  Google Scholar 

  157. FDA advises physicians of adverse events associated with the Cordis CYPHER coronary stents. US Food and Drug Administration Public Health Web Notifi cation. October 29, 2003; T03-T71. (Accessed at http://www.fda.gov/cdrh/safety/CYPHER3.html#footnote.).

    Google Scholar 

  158. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690.

    PubMed  Google Scholar 

  159. Schuhlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998;98:104.

    PubMed  CAS  Google Scholar 

  160. Chieffo A, Bonizzoni E, Orlic D, et al. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation 2004;109:2732.

    Article  PubMed  CAS  Google Scholar 

  161. Hasdai D, Garratt KN, Holmes DR Jr, et al. Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. J Am Coll Cardiol 1996;28:361.

    PubMed  CAS  Google Scholar 

  162. Regar E, Lemos PA, Saia F, et al. Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients. Am J Cardiol 2004;93:1271.

    Article  PubMed  Google Scholar 

  163. Costa MA, Sabat M, van der Giessen WJ, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999;100:789.

    PubMed  CAS  Google Scholar 

  164. Farb A, Burke AP, Kolodgie FD, et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003;108:1701.

    Article  PubMed  Google Scholar 

  165. Liistro F, Colombo A. Late acute thrombosis after paclitaxeleluting stent implantation. Heart 2001;86:262.

    Article  PubMed  CAS  Google Scholar 

  166. Sick P, Huttl T, Niebauer J, et al. Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis. Am J Cardiol 2003;91:148.

    Article  PubMed  Google Scholar 

  167. Sonoda S, Morino Y, Ako J, et al. An optimal diagnostic threshold of minimum stent area to predict long-term stent patency following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from SIRIUS Trial. J Am Coll Cardiol 2003;41:80A.

    Article  Google Scholar 

  168. Fujii K, Mintz GS, Kobayashi Y, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation 2004;109:1085.

    Article  PubMed  Google Scholar 

  169. Mintz GS, Shah VM, Weissman NJ. Regional remodeling as the cause of late stent malapposition. Circulation 2003;107:2660.

    Article  PubMed  Google Scholar 

  170. Shah VM, Mintz GS, Apple S, et al. Background incidence of late malapposition after bare-metal stent implantation. Circulation 2002;106:1753.

    Article  PubMed  CAS  Google Scholar 

  171. Ako J, Morino Y, Honda Y, et al. Late incomplete stent apposition following sirolimus-eluting stent: serial quantitative intravascular ultrasound analysis from the SIRIUS Trial. J Am Coll Cardiol 2003;41:33A.

    Article  Google Scholar 

  172. Degertekin M, Serruys PW, Tanabe K, et al. Long-term followup of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation 2003;108:2747.

    Article  PubMed  Google Scholar 

  173. Babapulle MN, Joseph L, Belise P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomized clinical trials of drug eluting stents. Lancet 2004:364:583–591.

    Article  PubMed  CAS  Google Scholar 

  174. Stone GW, Ellis SG, Cox DA, et al. One year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942–1947.

    Article  PubMed  CAS  Google Scholar 

  175. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315–1323.

    Article  PubMed  CAS  Google Scholar 

  176. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653–662.

    Article  PubMed  CAS  Google Scholar 

  177. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or siroliumus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663–670.

    Article  PubMed  CAS  Google Scholar 

  178. Morice MC, Serruys PW, Colombo A, et al. Eight-month outcome of the REALITY study: a prospective, randomized, multi-center head to head comparison of the sirolimus-eluting stent and the paclitaxel stent. Presented at the 2005 Annual Scientific Session of the American College of Cardiology, Orlando, FL, March 6–9.

    Google Scholar 

  179. Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology. J Am Coll Cardiol 2005;45:308–311.

    Article  PubMed  CAS  Google Scholar 

  180. Kastrati A, Mehilli J, von Beckerath N. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in stent restenosis. JAMA 2005;293:165–171.

    Article  PubMed  CAS  Google Scholar 

  181. Kastrati A, Dibra A, Eberle S. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005;294:819–825.

    Article  PubMed  CAS  Google Scholar 

  182. Rogers CD. Drug-eluting stents: clinical perspectives on drug and design differences. Rev Cardiovasc Med 2005;6(suppl 1):S3–S12.

    PubMed  Google Scholar 

  183. Fye WB. Introduction: The origins and implications of a growing shortage of cardiologists. J Am Coll Cardiol 2004;44:221.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Reading Hospital and Medical Center, Cardiology Associates of West Reading, West Reading, PA, USA

    Carey D. Moyer MD

  2. Interventional Cardiology, Geisinger Clinic, Danville, PA, USA

    Peter B. Berger MD

  3. Department of Cardiology, Ochsner Clinic Foundation, New Orleans, LA, USA

    Christopher J. White MD

Authors
  1. Carey D. Moyer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter B. Berger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher J. White MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Texas Health Science Center in Houston, Houston

    James T. Willerson MD (President, President-Elect and Medical Director) (President, President-Elect and Medical Director)

  2. Texas Heart Institute, Houston, TX, USA

    James T. Willerson MD (President, President-Elect and Medical Director) (President, President-Elect and Medical Director)

  3. Department of Cardiology, University of Maastricht, Masstricht, The Netherlands

    Hein J. J. Wellens MD (Emeritus Professor) (Emeritus Professor)

  4. Rasmussen Center for Cardiovascular Disease Prevention Cardiovascular Division, University of Minnesota, Minneapolis, MN, USA

    Jay N. Cohn MD (Professor of Medicine and Director) (Professor of Medicine and Director)

  5. Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA

    David R. Holmes Jr. MD (Consultant, Professor of Medicine and Scripps Professor) (Consultant, Professor of Medicine and Scripps Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag London Limited

About this chapter

Cite this chapter

Moyer, C.D., Berger, P.B., White, C.J. (2007). Drug-Eluting Coronary Stents. In: Willerson, J.T., Wellens, H.J.J., Cohn, J.N., Holmes, D.R. (eds) Cardiovascular Medicine. Springer, London. https://doi.org/10.1007/978-1-84628-715-2_48

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-715-2_48

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-188-4

  • Online ISBN: 978-1-84628-715-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation